LivaNova (NASDAQ:LIVN) Stock Price Breaks Below 50-Day Moving Average - What's Next?

Key Points

• LivaNova shares fell below their 50-day moving average, trading as low as $74.11 and last changing hands at $75.44, down 2.2%.
• Analyst sentiment remains positive overall, with a consensus “Moderate Buy” rating and an average price target of $84.12, despite one recent downgrade to “Hold.”
• The company exceeded quarterly expectations, reporting $1.26 in EPS and $390.59 million in revenue, while institutional investors own 97.64% of its stock and insiders have been net sellers recently.

LivaNova PLC (NASDAQ:LIVN - Get Free Report) crossed below its 50-day moving average during trading on Thursday. The stock has a 50-day moving average of $79.65 and traded as low as $74.11. LivaNova shares last traded at $75.44, with a volume of 1,056,361 shares trading hands.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. Needham & Company LLC increased their target price on LivaNova from $81.00 to $93.00 and gave the stock a "buy" rating in a research note on Wednesday, August 5th. Freedom Capital raised LivaNova to a "hold" rating in a research report on Tuesday, June 30th. KeyCorp boosted their price target on shares of LivaNova from $83.00 to $92.00 and gave the stock an "overweight" rating in a research note on Monday, June 22nd. Piper Sandler reissued an "overweight" rating and set a $90.00 price target (up from $87.00) on shares of LivaNova in a research report on Wednesday, September 2nd. Finally, Zacks Research lowered shares of LivaNova from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, August 19th. Six investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $84.12.

LivaNova Trading Down 2.2%

The company has a current ratio of 1.45, a quick ratio of 1.21 and a debt-to-equity ratio of 0.22. The company has a market cap of $4.16 billion, a PE ratio of 22.32 and a beta of 0.87. The company has a fifty day simple moving average of $79.65 and a two-hundred day simple moving average of $73.99.

LivaNova (NASDAQ:LIVN - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported $1.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.09 by $0.17. LivaNova had a return on equity of 16.35% and a net margin of 12.82%.The business had revenue of $390.59 million during the quarter, compared to analysts' expectations of $380.50 million. During the same quarter last year, the business posted $1.05 EPS. The business's quarterly revenue was up 10.8% compared to the same quarter last year. Analysts anticipate that LivaNova PLC will post 3.78 EPS for the current year.

Insider Buying and Selling at LivaNova

In related news, Director Brooke Story sold 2,300 shares of the stock in a transaction on Friday, September 4th. The stock was sold at an average price of $81.42, for a total value of $187,266.00. Following the transaction, the director owned 7,488 shares of the company's stock, valued at $609,672.96. This represents a 23.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Francesco Bianchi sold 3,500 shares of the firm's stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $78.01, for a total value of $273,035.00. Following the completion of the sale, the director owned 4,434 shares in the company, valued at approximately $345,896.34. This represents a 44.11% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 7,450 shares of company stock valued at $591,839. Corporate insiders own 0.35% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in LIVN. Millennium Management LLC lifted its stake in LivaNova by 17.3% during the fourth quarter. Millennium Management LLC now owns 3,484,082 shares of the company's stock worth $214,376,000 after purchasing an additional 514,268 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in LivaNova by 2.1% during the first quarter. Dimensional Fund Advisors LP now owns 1,826,248 shares of the company's stock worth $116,067,000 after purchasing an additional 38,320 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of LivaNova by 0.9% during the 4th quarter. Geode Capital Management LLC now owns 1,458,838 shares of the company's stock worth $89,775,000 after buying an additional 12,750 shares during the last quarter. Janus Henderson Group PLC lifted its position in shares of LivaNova by 1,978.8% during the 1st quarter. Janus Henderson Group PLC now owns 471,379 shares of the company's stock worth $29,961,000 after buying an additional 448,703 shares during the last quarter. Finally, Boone Capital Management LLC boosted its holdings in shares of LivaNova by 72.0% in the 4th quarter. Boone Capital Management LLC now owns 288,895 shares of the company's stock valued at $17,776,000 after buying an additional 120,963 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

LivaNova Company Profile

LivaNova PLC NASDAQ: LIVN is a medical device company that develops and manufactures technologies for the treatment of neurological and cardiovascular conditions. The company serves hospitals, physicians and patients in markets around the world, with operations and commercial activities spanning North America, Europe and other international markets.

LivaNova's Neuromodulation business produces vagus nerve stimulation (VNS) systems marketed under the VNS Therapy brand. These implantable devices are used as an adjunctive treatment for drug-resistant epilepsy and are designed to deliver programmed electrical stimulation to the vagus nerve.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.